Aarey Drugs & Pharmaceuticals (BOM:524412) Cyclically Adjusted Revenue per Share: ₹207.98 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524412 Aarey Drugs & Pharmaceuticals Ltd BOM:524412
54 GF Score
Price ₹89.16
GF Value ₹53.62
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Aarey Drugs & Pharmaceuticals Cyclically Adjusted Revenue per Share?

Aarey Drugs & Pharmaceuticals BOM:524412 +4.99% 54 Cyclically Adjusted Revenue per Share is ₹207.98 as of Jun. 2026. GuruFocus rates BOM:524412 with a GF Score™ of 54/100 and a GF Value™ of ₹53.62 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Aarey Drugs & Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹15.683. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹207.98 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Aarey Drugs & Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -1.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Aarey Drugs & Pharmaceuticals was 3.20% per year. The lowest was 1.50% per year. And the median was 2.60% per year.

As of today (2026-08-29), Aarey Drugs & Pharmaceuticals's current stock price is ₹89.16. Aarey Drugs & Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹207.98. Aarey Drugs & Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.43.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aarey Drugs & Pharmaceuticals was 0.45. The lowest was 0.12. And the median was 0.23.


Aarey Drugs & Pharmaceuticals  (BOM:524412) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aarey Drugs & Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=89.16/207.98
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aarey Drugs & Pharmaceuticals was 0.45. The lowest was 0.12. And the median was 0.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Aarey Drugs & Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Aarey Drugs & Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Aarey Drugs & Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarey Drugs & Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Aarey Drugs & Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 193.39 202.29 206.31 208.57 211.26

Aarey Drugs & Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 211.06 214.31 213.03 211.26 207.98

BOM:524412 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarey Drugs & Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarey Drugs & Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarey Drugs & Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aarey Drugs & Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:524412
54GF Score
Aarey Drugs & Pharmaceuticals Ltd BOM:524412
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarey Drugs & Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aarey Drugs & Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.683/167.3573*167.3573
=15.683

Current CPI (Jun. 2026) = 167.3573.

Aarey Drugs & Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 48.945 105.961 77.305
201612 54.715 105.196 87.047
201703 67.760 105.196 107.800
201706 40.658 107.109 63.528
201709 34.320 109.021 52.684
201712 44.694 109.404 68.369
201803 34.874 109.786 53.162
201806 28.849 111.317 43.373
201809 30.634 115.142 44.526
201812 33.541 115.142 48.751
201903 58.702 118.202 83.114
201906 28.310 120.880 39.195
201909 27.178 123.175 36.927
201912 25.526 126.235 33.841
202003 47.454 124.705 63.684
202006 10.784 127.000 14.211
202009 21.306 130.118 27.404
202012 40.677 130.889 52.010
202103 75.999 131.771 96.524
202106 41.701 134.084 52.049
202109 57.579 135.847 70.935
202112 55.256 138.161 66.933
202203 59.156 138.822 71.316
202206 46.815 142.347 55.040
202209 30.042 144.661 34.755
202212 24.609 145.763 28.255
202303 61.757 146.865 70.374
202306 20.073 150.280 22.354
202309 22.782 151.492 25.168
202312 30.127 152.924 32.970
202403 82.283 153.035 89.984
202406 45.238 155.789 48.597
202409 37.539 157.882 39.792
202412 47.019 158.323 49.702
202503 39.091 157.552 41.524
202506 35.776 159.755 37.478
202509 29.594 162.289 30.518
202512 33.888 163.281 34.734
202603 66.914 164.272 68.171
202606 15.683 167.357 15.683

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹207.98 mean?
Aarey Drugs & Pharmaceuticals (BOM:524412) has a Cyclically Adjusted Revenue per Share of ₹207.98 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aarey Drugs & Pharmaceuticals and its competitors.
Is Aarey Drugs & Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Aarey Drugs & Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹207.98. Overall, Aarey Drugs & Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarey Drugs & Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Aarey Drugs & Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹207.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aarey Drugs & Pharmaceuticals and its competitors. Aarey Drugs & Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹207.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarey Drugs & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals (BOM:524412) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹53.62, compared to a current price of ₹89.16 — trading 66.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹207.98. Aarey Drugs & Pharmaceuticals' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Aarey Drugs & Pharmaceuticals (BOM:524412), the current Cyclically Adjusted Revenue per Share is ₹207.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarey Drugs & Pharmaceuticals (BOM:524412) Overvalued in 2026?

Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued. The current stock price of ₹89.16 is trading 66.3% above its estimated GF Value™ of ₹53.62. GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524412:

  • Cyclically Adjusted Revenue per Share: ₹207.98
  • GF Value™: ₹53.62 vs. price of ₹89.16 (66.3% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the BOM:524412 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarey Drugs & Pharmaceuticals Business Description

Other Exchanges AAREYDRUGS:India
Address 340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid Bunder, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
54GF Score

Get the complete analysis for BOM:524412

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹89.16
Price
₹53.62
GF Value